Apogee Q3 2024 Earnings Report
Key Takeaways
Apogee Therapeutics reported its Q3 2024 financial results, highlighting continued execution across all programs, including positive results from the APG777 Phase 1 trial. The company is on track to report Phase 2 Part A data for APG777 in 2H 2025, interim Phase 1 data for APG808 in 4Q 2024, and interim Phase 1 data for APG990 in 1H 2025. Apogee had $753.8 million in cash, cash equivalents, and marketable securities, providing runway into 2028.
Reported positive results up to nine months from APG777 Phase 1 trial.
On track to report Phase 2 Part A data for APG777 in 2H 2025, interim Phase 1 data for APG808 in 4Q 2024 and interim Phase 1 data for APG990 in 1H 2025.
APG333 development candidate selected and accelerating initiation of Phase 1 in late 2024 or early 2025.
Cash, cash equivalents and marketable securities of $753.8 million with runway into 2028.